nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—Bronchopneumonia—Liotrix—hypothyroidism	0.0208	0.0374	CcSEcCtD
Thalidomide—Menadione—BGLAP—hypothyroidism	0.0179	1	CrCbGaD
Thalidomide—CYP2C19—urine—hypothyroidism	0.0122	0.0398	CbGeAlD
Thalidomide—TNF—blood—hypothyroidism	0.0121	0.0396	CbGeAlD
Thalidomide—Intestinal perforation—Liotrix—hypothyroidism	0.0115	0.0207	CcSEcCtD
Thalidomide—Cardiac failure congestive—Liothyronine—hypothyroidism	0.01	0.0181	CcSEcCtD
Thalidomide—CYP1A2—urine—hypothyroidism	0.00995	0.0325	CbGeAlD
Thalidomide—CYP2C9—urine—hypothyroidism	0.00944	0.0309	CbGeAlD
Thalidomide—NFKB1—heart—hypothyroidism	0.00925	0.0302	CbGeAlD
Thalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—NEFH—hypothyroidism	0.00912	0.0751	CbGpPWpGaD
Thalidomide—CYP2E1—urine—hypothyroidism	0.00895	0.0293	CbGeAlD
Thalidomide—NFKB1—cardiovascular system—hypothyroidism	0.00873	0.0285	CbGeAlD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—POU1F1—hypothyroidism	0.00854	0.0703	CbGpPWpGaD
Thalidomide—Venous thrombosis—Liotrix—hypothyroidism	0.0084	0.0151	CcSEcCtD
Thalidomide—CRBN—adrenal cortex—hypothyroidism	0.00802	0.0262	CbGeAlD
Thalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—THRA—hypothyroidism	0.00797	0.0656	CbGpPWpGaD
Thalidomide—NFKB1—gonad—hypothyroidism	0.00792	0.0259	CbGeAlD
Thalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—NEFM—hypothyroidism	0.00776	0.0638	CbGpPWpGaD
Thalidomide—CRBN—heart—hypothyroidism	0.00775	0.0254	CbGeAlD
Thalidomide—NFKB1—pituitary gland—hypothyroidism	0.00773	0.0253	CbGeAlD
Thalidomide—Angina pectoris—Liothyronine—hypothyroidism	0.00767	0.0138	CcSEcCtD
Thalidomide—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00692	0.0125	CcSEcCtD
Thalidomide—NFKB1—adrenal gland—hypothyroidism	0.00691	0.0226	CbGeAlD
Thalidomide—NFKB1—blood—hypothyroidism	0.0069	0.0226	CbGeAlD
Thalidomide—Myocardial infarction—Liothyronine—hypothyroidism	0.00688	0.0124	CcSEcCtD
Thalidomide—NFKB1—thyroid gland—hypothyroidism	0.00666	0.0218	CbGeAlD
Thalidomide—Intestinal obstruction—Liotrix—hypothyroidism	0.00665	0.012	CcSEcCtD
Thalidomide—CRBN—gonad—hypothyroidism	0.00664	0.0217	CbGeAlD
Thalidomide—FGFR2—cardiovascular system—hypothyroidism	0.00656	0.0214	CbGeAlD
Thalidomide—TNF—EV release from cardiac cells and their functional effects—PRL—hypothyroidism	0.00655	0.0539	CbGpPWpGaD
Thalidomide—CRBN—pituitary gland—hypothyroidism	0.00648	0.0212	CbGeAlD
Thalidomide—NFKB1—female gonad—hypothyroidism	0.00644	0.0211	CbGeAlD
Thalidomide—Cyanosis—Liotrix—hypothyroidism	0.0064	0.0115	CcSEcCtD
Thalidomide—CRBN—adrenal gland—hypothyroidism	0.00579	0.0189	CbGeAlD
Thalidomide—CRBN—blood—hypothyroidism	0.00579	0.0189	CbGeAlD
Thalidomide—NFKB1—testis—hypothyroidism	0.00571	0.0187	CbGeAlD
Thalidomide—Tingling sensation—Liotrix—hypothyroidism	0.00564	0.0102	CcSEcCtD
Thalidomide—Arrhythmia—Liothyronine—hypothyroidism	0.00563	0.0101	CcSEcCtD
Thalidomide—CRBN—thyroid gland—hypothyroidism	0.00559	0.0183	CbGeAlD
Thalidomide—TNF—Monoamine Transport—SLC5A7—hypothyroidism	0.0055	0.0453	CbGpPWpGaD
Thalidomide—NFKB1—liver—hypothyroidism	0.0054	0.0177	CbGeAlD
Thalidomide—CRBN—female gonad—hypothyroidism	0.0054	0.0176	CbGeAlD
Thalidomide—Hyperkinesia—Levothyroxine—hypothyroidism	0.00537	0.00969	CcSEcCtD
Thalidomide—Hyperkinesia—Dextrothyroxine—hypothyroidism	0.00537	0.00969	CcSEcCtD
Thalidomide—NFKB1—cerebellum—hypothyroidism	0.00527	0.0172	CbGeAlD
Thalidomide—FGFR2—adrenal gland—hypothyroidism	0.00519	0.017	CbGeAlD
Thalidomide—FGFR2—blood—hypothyroidism	0.00519	0.017	CbGeAlD
Thalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—THRB—hypothyroidism	0.00513	0.0422	CbGpPWpGaD
Thalidomide—FGFR2—thyroid gland—hypothyroidism	0.005	0.0164	CbGeAlD
Thalidomide—Cellulitis—Liotrix—hypothyroidism	0.00498	0.00899	CcSEcCtD
Thalidomide—Hypocalcaemia—Liotrix—hypothyroidism	0.00495	0.00893	CcSEcCtD
Thalidomide—Cardiac failure congestive—Dextrothyroxine—hypothyroidism	0.00493	0.00889	CcSEcCtD
Thalidomide—Cardiac failure congestive—Levothyroxine—hypothyroidism	0.00493	0.00889	CcSEcCtD
Thalidomide—Oliguria—Liotrix—hypothyroidism	0.00492	0.00887	CcSEcCtD
Thalidomide—FGFR2—female gonad—hypothyroidism	0.00484	0.0158	CbGeAlD
Thalidomide—CRBN—testis—hypothyroidism	0.00479	0.0156	CbGeAlD
Thalidomide—Creatinine increased—Liotrix—hypothyroidism	0.00476	0.00858	CcSEcCtD
Thalidomide—Increased appetite—Levothyroxine—hypothyroidism	0.00476	0.00858	CcSEcCtD
Thalidomide—Increased appetite—Dextrothyroxine—hypothyroidism	0.00476	0.00858	CcSEcCtD
Thalidomide—Hypertension—Liothyronine—hypothyroidism	0.00474	0.00854	CcSEcCtD
Thalidomide—Cardiac failure—Dextrothyroxine—hypothyroidism	0.00458	0.00826	CcSEcCtD
Thalidomide—Hypoglycaemia—Levothyroxine—hypothyroidism	0.00458	0.00826	CcSEcCtD
Thalidomide—Cardiac failure—Levothyroxine—hypothyroidism	0.00458	0.00826	CcSEcCtD
Thalidomide—Hypoglycaemia—Dextrothyroxine—hypothyroidism	0.00458	0.00826	CcSEcCtD
Thalidomide—CRBN—liver—hypothyroidism	0.00453	0.0148	CbGeAlD
Thalidomide—CRBN—cerebellum—hypothyroidism	0.00442	0.0145	CbGeAlD
Thalidomide—Affect lability—Dextrothyroxine—hypothyroidism	0.0044	0.00794	CcSEcCtD
Thalidomide—Affect lability—Levothyroxine—hypothyroidism	0.0044	0.00794	CcSEcCtD
Thalidomide—Tachycardia—Liothyronine—hypothyroidism	0.00437	0.00788	CcSEcCtD
Thalidomide—FGFR2—testis—hypothyroidism	0.00429	0.014	CbGeAlD
Thalidomide—Blood urea increased—Liotrix—hypothyroidism	0.00428	0.00772	CcSEcCtD
Thalidomide—Cardiac arrest—Dextrothyroxine—hypothyroidism	0.00425	0.00767	CcSEcCtD
Thalidomide—Cardiac arrest—Levothyroxine—hypothyroidism	0.00425	0.00767	CcSEcCtD
Thalidomide—Mood swings—Levothyroxine—hypothyroidism	0.00424	0.00764	CcSEcCtD
Thalidomide—Mood swings—Dextrothyroxine—hypothyroidism	0.00424	0.00764	CcSEcCtD
Thalidomide—Hypotension—Liothyronine—hypothyroidism	0.00418	0.00754	CcSEcCtD
Thalidomide—Dehydration—Dextrothyroxine—hypothyroidism	0.00416	0.0075	CcSEcCtD
Thalidomide—Dehydration—Levothyroxine—hypothyroidism	0.00416	0.0075	CcSEcCtD
Thalidomide—Lightheadedness—Liotrix—hypothyroidism	0.00406	0.00731	CcSEcCtD
Thalidomide—FGFR2—liver—hypothyroidism	0.00405	0.0133	CbGeAlD
Thalidomide—FGFR2—cerebellum—hypothyroidism	0.00396	0.013	CbGeAlD
Thalidomide—Hyperkinesia—Liotrix—hypothyroidism	0.00395	0.00713	CcSEcCtD
Thalidomide—Muscular weakness—Levothyroxine—hypothyroidism	0.00395	0.00711	CcSEcCtD
Thalidomide—Muscular weakness—Dextrothyroxine—hypothyroidism	0.00395	0.00711	CcSEcCtD
Thalidomide—Sepsis—Liotrix—hypothyroidism	0.00393	0.00709	CcSEcCtD
Thalidomide—Dysphagia—Levothyroxine—hypothyroidism	0.00387	0.00697	CcSEcCtD
Thalidomide—Dysphagia—Dextrothyroxine—hypothyroidism	0.00387	0.00697	CcSEcCtD
Thalidomide—Angina pectoris—Dextrothyroxine—hypothyroidism	0.00377	0.00679	CcSEcCtD
Thalidomide—Angina pectoris—Levothyroxine—hypothyroidism	0.00377	0.00679	CcSEcCtD
Thalidomide—Cardiac failure congestive—Liotrix—hypothyroidism	0.00363	0.00654	CcSEcCtD
Thalidomide—Renal failure acute—Liotrix—hypothyroidism	0.00356	0.00643	CcSEcCtD
Thalidomide—Body temperature increased—Liothyronine—hypothyroidism	0.00354	0.00638	CcSEcCtD
Thalidomide—Increased appetite—Liotrix—hypothyroidism	0.0035	0.00631	CcSEcCtD
Thalidomide—Weight decreased—Levothyroxine—hypothyroidism	0.0035	0.00631	CcSEcCtD
Thalidomide—Weight decreased—Dextrothyroxine—hypothyroidism	0.0035	0.00631	CcSEcCtD
Thalidomide—NFKB1—EPO signaling pathway—SH2B3—hypothyroidism	0.00344	0.0283	CbGpPWpGaD
Thalidomide—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.0034	0.00613	CcSEcCtD
Thalidomide—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.0034	0.00613	CcSEcCtD
Thalidomide—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00338	0.00609	CcSEcCtD
Thalidomide—Myocardial infarction—Levothyroxine—hypothyroidism	0.00338	0.00609	CcSEcCtD
Thalidomide—Cardiac failure—Liotrix—hypothyroidism	0.00337	0.00608	CcSEcCtD
Thalidomide—Hypoglycaemia—Liotrix—hypothyroidism	0.00337	0.00608	CcSEcCtD
Thalidomide—Cerebrovascular accident—Liotrix—hypothyroidism	0.00336	0.00605	CcSEcCtD
Thalidomide—Sweating—Dextrothyroxine—hypothyroidism	0.0033	0.00596	CcSEcCtD
Thalidomide—Sweating—Levothyroxine—hypothyroidism	0.0033	0.00596	CcSEcCtD
Thalidomide—Affect lability—Liotrix—hypothyroidism	0.00324	0.00584	CcSEcCtD
Thalidomide—Cardiac arrest—Liotrix—hypothyroidism	0.00313	0.00564	CcSEcCtD
Thalidomide—Mood swings—Liotrix—hypothyroidism	0.00312	0.00562	CcSEcCtD
Thalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—NEFL—hypothyroidism	0.00309	0.0254	CbGpPWpGaD
Thalidomide—Blood creatinine increased—Liotrix—hypothyroidism	0.00308	0.00556	CcSEcCtD
Thalidomide—Dehydration—Liotrix—hypothyroidism	0.00306	0.00552	CcSEcCtD
Thalidomide—Hypokalaemia—Liotrix—hypothyroidism	0.00299	0.0054	CcSEcCtD
Thalidomide—Muscular weakness—Liotrix—hypothyroidism	0.0029	0.00523	CcSEcCtD
Thalidomide—Abdominal distension—Liotrix—hypothyroidism	0.00286	0.00516	CcSEcCtD
Thalidomide—Dysphagia—Liotrix—hypothyroidism	0.00284	0.00513	CcSEcCtD
Thalidomide—Bronchospasm—Liotrix—hypothyroidism	0.0028	0.00504	CcSEcCtD
Thalidomide—Angina pectoris—Liotrix—hypothyroidism	0.00277	0.00499	CcSEcCtD
Thalidomide—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00276	0.00498	CcSEcCtD
Thalidomide—Arrhythmia—Levothyroxine—hypothyroidism	0.00276	0.00498	CcSEcCtD
Thalidomide—Bronchitis—Liotrix—hypothyroidism	0.00274	0.00493	CcSEcCtD
Thalidomide—Alopecia—Levothyroxine—hypothyroidism	0.00273	0.00493	CcSEcCtD
Thalidomide—Alopecia—Dextrothyroxine—hypothyroidism	0.00273	0.00493	CcSEcCtD
Thalidomide—Tension—Dextrothyroxine—hypothyroidism	0.00264	0.00477	CcSEcCtD
Thalidomide—Tension—Levothyroxine—hypothyroidism	0.00264	0.00477	CcSEcCtD
Thalidomide—Nervousness—Levothyroxine—hypothyroidism	0.00262	0.00472	CcSEcCtD
Thalidomide—Nervousness—Dextrothyroxine—hypothyroidism	0.00262	0.00472	CcSEcCtD
Thalidomide—Weight decreased—Liotrix—hypothyroidism	0.00257	0.00464	CcSEcCtD
Thalidomide—Tremor—Dextrothyroxine—hypothyroidism	0.00252	0.00455	CcSEcCtD
Thalidomide—Tremor—Levothyroxine—hypothyroidism	0.00252	0.00455	CcSEcCtD
Thalidomide—CYP1A1—heart—hypothyroidism	0.00251	0.00822	CbGeAlD
Thalidomide—Acute coronary syndrome—Liotrix—hypothyroidism	0.0025	0.00451	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.00249	0.0205	CbGpPWpGaD
Thalidomide—Renal failure—Liotrix—hypothyroidism	0.00249	0.00449	CcSEcCtD
Thalidomide—Myocardial infarction—Liotrix—hypothyroidism	0.00249	0.00448	CcSEcCtD
Thalidomide—Agitation—Dextrothyroxine—hypothyroidism	0.00248	0.00446	CcSEcCtD
Thalidomide—Agitation—Levothyroxine—hypothyroidism	0.00248	0.00446	CcSEcCtD
Thalidomide—Angioedema—Levothyroxine—hypothyroidism	0.00246	0.00444	CcSEcCtD
Thalidomide—Angioedema—Dextrothyroxine—hypothyroidism	0.00246	0.00444	CcSEcCtD
Thalidomide—Sweating—Liotrix—hypothyroidism	0.00243	0.00438	CcSEcCtD
Thalidomide—CYP2C9—heart—hypothyroidism	0.00242	0.00791	CbGeAlD
Thalidomide—NFKB1—Osteopontin-mediated events—VAV3—hypothyroidism	0.00242	0.0199	CbGpPWpGaD
Thalidomide—Palpitations—Dextrothyroxine—hypothyroidism	0.00238	0.00429	CcSEcCtD
Thalidomide—Palpitations—Levothyroxine—hypothyroidism	0.00238	0.00429	CcSEcCtD
Thalidomide—Convulsion—Dextrothyroxine—hypothyroidism	0.00233	0.00421	CcSEcCtD
Thalidomide—Convulsion—Levothyroxine—hypothyroidism	0.00233	0.00421	CcSEcCtD
Thalidomide—CYP2C19—blood—hypothyroidism	0.00233	0.00761	CbGeAlD
Thalidomide—Arthralgia—Dextrothyroxine—hypothyroidism	0.00229	0.00413	CcSEcCtD
Thalidomide—Arthralgia—Levothyroxine—hypothyroidism	0.00229	0.00413	CcSEcCtD
Thalidomide—Anxiety—Levothyroxine—hypothyroidism	0.00229	0.00412	CcSEcCtD
Thalidomide—Anxiety—Dextrothyroxine—hypothyroidism	0.00229	0.00412	CcSEcCtD
Thalidomide—CYP2C9—cardiovascular system—hypothyroidism	0.00228	0.00747	CbGeAlD
Thalidomide—Hypoaesthesia—Liotrix—hypothyroidism	0.00226	0.00408	CcSEcCtD
Thalidomide—Confusional state—Dextrothyroxine—hypothyroidism	0.00222	0.004	CcSEcCtD
Thalidomide—Confusional state—Levothyroxine—hypothyroidism	0.00222	0.004	CcSEcCtD
Thalidomide—PTGS1—heart—hypothyroidism	0.00221	0.00722	CbGeAlD
Thalidomide—PTGS2—adrenal cortex—hypothyroidism	0.00218	0.00714	CbGeAlD
Thalidomide—CYP2E1—cardiovascular system—hypothyroidism	0.00216	0.00707	CbGeAlD
Thalidomide—Shock—Levothyroxine—hypothyroidism	0.00216	0.0039	CcSEcCtD
Thalidomide—Shock—Dextrothyroxine—hypothyroidism	0.00216	0.0039	CcSEcCtD
Thalidomide—FGFR2—FGF signaling pathway—BGLAP—hypothyroidism	0.00216	0.0178	CbGpPWpGaD
Thalidomide—Tachycardia—Dextrothyroxine—hypothyroidism	0.00215	0.00387	CcSEcCtD
Thalidomide—Tachycardia—Levothyroxine—hypothyroidism	0.00215	0.00387	CcSEcCtD
Thalidomide—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00213	0.00383	CcSEcCtD
Thalidomide—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00213	0.00383	CcSEcCtD
Thalidomide—PTGS2—heart—hypothyroidism	0.00211	0.0069	CbGeAlD
Thalidomide—PTGS1—cardiovascular system—hypothyroidism	0.00208	0.00682	CbGeAlD
Thalidomide—Arrhythmia—Liotrix—hypothyroidism	0.00203	0.00367	CcSEcCtD
Thalidomide—Alopecia—Liotrix—hypothyroidism	0.00201	0.00363	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.002	0.00361	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.002	0.00361	CcSEcCtD
Thalidomide—PTGS2—cardiovascular system—hypothyroidism	0.00199	0.00651	CbGeAlD
Thalidomide—Insomnia—Levothyroxine—hypothyroidism	0.00199	0.00358	CcSEcCtD
Thalidomide—Insomnia—Dextrothyroxine—hypothyroidism	0.00199	0.00358	CcSEcCtD
Thalidomide—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00196	0.00353	CcSEcCtD
Thalidomide—Dyspnoea—Levothyroxine—hypothyroidism	0.00196	0.00353	CcSEcCtD
Thalidomide—Flatulence—Liotrix—hypothyroidism	0.00195	0.00352	CcSEcCtD
Thalidomide—Tension—Liotrix—hypothyroidism	0.00194	0.00351	CcSEcCtD
Thalidomide—Dysgeusia—Liotrix—hypothyroidism	0.00194	0.0035	CcSEcCtD
Thalidomide—Nervousness—Liotrix—hypothyroidism	0.00192	0.00347	CcSEcCtD
Thalidomide—CYP1A2—blood—hypothyroidism	0.0019	0.00622	CbGeAlD
Thalidomide—TNF—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.0019	0.0156	CbGpPWpGaD
Thalidomide—Fatigue—Levothyroxine—hypothyroidism	0.0019	0.00342	CcSEcCtD
Thalidomide—Fatigue—Dextrothyroxine—hypothyroidism	0.0019	0.00342	CcSEcCtD
Thalidomide—CYP1A1—blood—hypothyroidism	0.00188	0.00613	CbGeAlD
Thalidomide—Vision blurred—Liotrix—hypothyroidism	0.00187	0.00337	CcSEcCtD
Thalidomide—Tremor—Liotrix—hypothyroidism	0.00186	0.00335	CcSEcCtD
Thalidomide—PTGS1—pituitary gland—hypothyroidism	0.00185	0.00603	CbGeAlD
Thalidomide—CYP1A2—thyroid gland—hypothyroidism	0.00184	0.006	CbGeAlD
Thalidomide—CYP3A5—blood—hypothyroidism	0.00183	0.006	CbGeAlD
Thalidomide—CYP2C19—liver—hypothyroidism	0.00182	0.00595	CbGeAlD
Thalidomide—Agitation—Liotrix—hypothyroidism	0.00182	0.00328	CcSEcCtD
Thalidomide—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00181	0.00327	CcSEcCtD
Thalidomide—Feeling abnormal—Levothyroxine—hypothyroidism	0.00181	0.00327	CcSEcCtD
Thalidomide—CYP1A1—thyroid gland—hypothyroidism	0.00181	0.00592	CbGeAlD
Thalidomide—Angioedema—Liotrix—hypothyroidism	0.00181	0.00326	CcSEcCtD
Thalidomide—CYP2C9—blood—hypothyroidism	0.00181	0.0059	CbGeAlD
Thalidomide—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.0018	0.00324	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.0018	0.00324	CcSEcCtD
Thalidomide—Syncope—Liotrix—hypothyroidism	0.00178	0.0032	CcSEcCtD
Thalidomide—PTGS2—pituitary gland—hypothyroidism	0.00176	0.00577	CbGeAlD
Thalidomide—Palpitations—Liotrix—hypothyroidism	0.00175	0.00316	CcSEcCtD
Thalidomide—CYP1A1—female gonad—hypothyroidism	0.00175	0.00572	CbGeAlD
Thalidomide—Urticaria—Dextrothyroxine—hypothyroidism	0.00175	0.00315	CcSEcCtD
Thalidomide—Urticaria—Levothyroxine—hypothyroidism	0.00175	0.00315	CcSEcCtD
Thalidomide—Loss of consciousness—Liotrix—hypothyroidism	0.00174	0.00314	CcSEcCtD
Thalidomide—Body temperature increased—Levothyroxine—hypothyroidism	0.00174	0.00313	CcSEcCtD
Thalidomide—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00174	0.00313	CcSEcCtD
Thalidomide—Abdominal pain—Levothyroxine—hypothyroidism	0.00174	0.00313	CcSEcCtD
Thalidomide—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00174	0.00313	CcSEcCtD
Thalidomide—Convulsion—Liotrix—hypothyroidism	0.00172	0.0031	CcSEcCtD
Thalidomide—CYP2E1—adrenal gland—hypothyroidism	0.00171	0.0056	CbGeAlD
Thalidomide—CYP2E1—blood—hypothyroidism	0.00171	0.00559	CbGeAlD
Thalidomide—CYP3A5—female gonad—hypothyroidism	0.00171	0.00559	CbGeAlD
Thalidomide—Hypertension—Liotrix—hypothyroidism	0.00171	0.00308	CcSEcCtD
Thalidomide—Arthralgia—Liotrix—hypothyroidism	0.00169	0.00304	CcSEcCtD
Thalidomide—Chest pain—Liotrix—hypothyroidism	0.00169	0.00304	CcSEcCtD
Thalidomide—Anxiety—Liotrix—hypothyroidism	0.00168	0.00303	CcSEcCtD
Thalidomide—CYP2E1—thyroid gland—hypothyroidism	0.00165	0.0054	CbGeAlD
Thalidomide—PTGS1—adrenal gland—hypothyroidism	0.00165	0.00539	CbGeAlD
Thalidomide—PTGS1—blood—hypothyroidism	0.00165	0.00539	CbGeAlD
Thalidomide—Confusional state—Liotrix—hypothyroidism	0.00163	0.00294	CcSEcCtD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—BGLAP—hypothyroidism	0.00163	0.0134	CbGpPWpGaD
Thalidomide—Oedema—Liotrix—hypothyroidism	0.00162	0.00292	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.00161	0.0132	CbGpPWpGaD
Thalidomide—Infection—Liotrix—hypothyroidism	0.00161	0.0029	CcSEcCtD
Thalidomide—PTGS1—Prostaglandin Synthesis and Regulation—PRL—hypothyroidism	0.00159	0.0131	CbGpPWpGaD
Thalidomide—Shock—Liotrix—hypothyroidism	0.00159	0.00287	CcSEcCtD
Thalidomide—PTGS1—thyroid gland—hypothyroidism	0.00159	0.0052	CbGeAlD
Thalidomide—Tachycardia—Liotrix—hypothyroidism	0.00158	0.00285	CcSEcCtD
Thalidomide—Asthenia—Dextrothyroxine—hypothyroidism	0.00158	0.00284	CcSEcCtD
Thalidomide—Asthenia—Levothyroxine—hypothyroidism	0.00158	0.00284	CcSEcCtD
Thalidomide—PTGS2—adrenal gland—hypothyroidism	0.00158	0.00515	CbGeAlD
Thalidomide—PTGS2—blood—hypothyroidism	0.00158	0.00515	CbGeAlD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—VAV3—hypothyroidism	0.00157	0.013	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Liotrix—hypothyroidism	0.00156	0.00282	CcSEcCtD
Thalidomide—Pruritus—Levothyroxine—hypothyroidism	0.00156	0.0028	CcSEcCtD
Thalidomide—Pruritus—Dextrothyroxine—hypothyroidism	0.00156	0.0028	CcSEcCtD
Thalidomide—Anorexia—Liotrix—hypothyroidism	0.00154	0.00278	CcSEcCtD
Thalidomide—PTGS1—female gonad—hypothyroidism	0.00154	0.00503	CbGeAlD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—PIK3C2A—hypothyroidism	0.00154	0.0126	CbGpPWpGaD
Thalidomide—Hypotension—Liotrix—hypothyroidism	0.00151	0.00272	CcSEcCtD
Thalidomide—Diarrhoea—Levothyroxine—hypothyroidism	0.0015	0.00271	CcSEcCtD
Thalidomide—Diarrhoea—Dextrothyroxine—hypothyroidism	0.0015	0.00271	CcSEcCtD
Thalidomide—NFKB1—TCR Signaling Pathway—SH2B3—hypothyroidism	0.0015	0.0124	CbGpPWpGaD
Thalidomide—CYP1A2—liver—hypothyroidism	0.00149	0.00486	CbGeAlD
Thalidomide—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00147	0.00266	CcSEcCtD
Thalidomide—PTGS2—female gonad—hypothyroidism	0.00147	0.0048	CbGeAlD
Thalidomide—CYP1A1—liver—hypothyroidism	0.00147	0.0048	CbGeAlD
Thalidomide—Insomnia—Liotrix—hypothyroidism	0.00146	0.00264	CcSEcCtD
Thalidomide—Paraesthesia—Liotrix—hypothyroidism	0.00145	0.00262	CcSEcCtD
Thalidomide—Dyspnoea—Liotrix—hypothyroidism	0.00144	0.0026	CcSEcCtD
Thalidomide—CYP3A5—liver—hypothyroidism	0.00143	0.00469	CbGeAlD
Thalidomide—CYP2E1—testis—hypothyroidism	0.00142	0.00463	CbGeAlD
Thalidomide—CYP2C9—liver—hypothyroidism	0.00141	0.00462	CbGeAlD
Thalidomide—Decreased appetite—Liotrix—hypothyroidism	0.00141	0.00253	CcSEcCtD
Thalidomide—Vomiting—Levothyroxine—hypothyroidism	0.0014	0.00252	CcSEcCtD
Thalidomide—Vomiting—Dextrothyroxine—hypothyroidism	0.0014	0.00252	CcSEcCtD
Thalidomide—Fatigue—Liotrix—hypothyroidism	0.00139	0.00251	CcSEcCtD
Thalidomide—Rash—Dextrothyroxine—hypothyroidism	0.00139	0.0025	CcSEcCtD
Thalidomide—Rash—Levothyroxine—hypothyroidism	0.00139	0.0025	CcSEcCtD
Thalidomide—Dermatitis—Levothyroxine—hypothyroidism	0.00138	0.0025	CcSEcCtD
Thalidomide—Dermatitis—Dextrothyroxine—hypothyroidism	0.00138	0.0025	CcSEcCtD
Thalidomide—Constipation—Liotrix—hypothyroidism	0.00138	0.00249	CcSEcCtD
Thalidomide—Headache—Dextrothyroxine—hypothyroidism	0.00138	0.00248	CcSEcCtD
Thalidomide—Headache—Levothyroxine—hypothyroidism	0.00138	0.00248	CcSEcCtD
Thalidomide—PTGS1—testis—hypothyroidism	0.00136	0.00446	CbGeAlD
Thalidomide—CYP2E1—liver—hypothyroidism	0.00134	0.00438	CbGeAlD
Thalidomide—Feeling abnormal—Liotrix—hypothyroidism	0.00133	0.0024	CcSEcCtD
Thalidomide—Gastrointestinal pain—Liotrix—hypothyroidism	0.00132	0.00238	CcSEcCtD
Thalidomide—CYP2E1—cerebellum—hypothyroidism	0.00131	0.00427	CbGeAlD
Thalidomide—Nausea—Levothyroxine—hypothyroidism	0.00131	0.00235	CcSEcCtD
Thalidomide—Nausea—Dextrothyroxine—hypothyroidism	0.00131	0.00235	CcSEcCtD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—PIK3C2A—hypothyroidism	0.00129	0.0106	CbGpPWpGaD
Thalidomide—Urticaria—Liotrix—hypothyroidism	0.00128	0.00232	CcSEcCtD
Thalidomide—Abdominal pain—Liotrix—hypothyroidism	0.00128	0.0023	CcSEcCtD
Thalidomide—Body temperature increased—Liotrix—hypothyroidism	0.00128	0.0023	CcSEcCtD
Thalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PRL—hypothyroidism	0.00126	0.0104	CbGpPWpGaD
Thalidomide—PTGS2—liver—hypothyroidism	0.00123	0.00403	CbGeAlD
Thalidomide—TNF—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.00122	0.0101	CbGpPWpGaD
Thalidomide—PTGS2—cerebellum—hypothyroidism	0.0012	0.00394	CbGeAlD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—PRL—hypothyroidism	0.0012	0.00988	CbGpPWpGaD
Thalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—VAV3—hypothyroidism	0.0012	0.00987	CbGpPWpGaD
Thalidomide—Hypersensitivity—Liotrix—hypothyroidism	0.00119	0.00215	CcSEcCtD
Thalidomide—Asthenia—Liotrix—hypothyroidism	0.00116	0.00209	CcSEcCtD
Thalidomide—Pruritus—Liotrix—hypothyroidism	0.00114	0.00206	CcSEcCtD
Thalidomide—NFKB1—p75 NTR receptor-mediated signalling—VAV3—hypothyroidism	0.00111	0.00914	CbGpPWpGaD
Thalidomide—Diarrhoea—Liotrix—hypothyroidism	0.00111	0.00199	CcSEcCtD
Thalidomide—Dizziness—Liotrix—hypothyroidism	0.00107	0.00193	CcSEcCtD
Thalidomide—NFKB1—Ceramide signaling pathway—IGF1—hypothyroidism	0.00105	0.00864	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—VAV3—hypothyroidism	0.00103	0.00848	CbGpPWpGaD
Thalidomide—Vomiting—Liotrix—hypothyroidism	0.00103	0.00185	CcSEcCtD
Thalidomide—Rash—Liotrix—hypothyroidism	0.00102	0.00184	CcSEcCtD
Thalidomide—Dermatitis—Liotrix—hypothyroidism	0.00102	0.00184	CcSEcCtD
Thalidomide—Headache—Liotrix—hypothyroidism	0.00101	0.00183	CcSEcCtD
Thalidomide—FGFR2—Signaling by SCF-KIT—SH2B3—hypothyroidism	0.000995	0.00819	CbGpPWpGaD
Thalidomide—Nausea—Liotrix—hypothyroidism	0.000961	0.00173	CcSEcCtD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—PIK3C2A—hypothyroidism	0.000952	0.00784	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—IGF1—hypothyroidism	0.000942	0.00775	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—IGF1—hypothyroidism	0.000893	0.00735	CbGpPWpGaD
Thalidomide—TNF—Ceramide signaling pathway—IGF1—hypothyroidism	0.0008	0.00658	CbGpPWpGaD
Thalidomide—TNF—Cardiac Hypertrophic Response—IGF1—hypothyroidism	0.000717	0.0059	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—POMC—hypothyroidism	0.000711	0.00585	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—VAV3—hypothyroidism	0.000708	0.00583	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—PRL—hypothyroidism	0.000695	0.00572	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—IGF1—hypothyroidism	0.000671	0.00552	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—IGF1—hypothyroidism	0.000671	0.00552	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—POMC—hypothyroidism	0.000649	0.00534	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.00064	0.00526	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—IGF1—hypothyroidism	0.000637	0.00524	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events triggered by IGF1R—IGF1—hypothyroidism	0.000608	0.005	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—VAV3—hypothyroidism	0.000605	0.00498	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—VAV3—hypothyroidism	0.0006	0.00494	CbGpPWpGaD
Thalidomide—FGFR2—IGF1R signaling cascade—IGF1—hypothyroidism	0.000592	0.00487	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—VAV3—hypothyroidism	0.000569	0.00469	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—VAV3—hypothyroidism	0.000569	0.00469	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CLTC—hypothyroidism	0.00056	0.00461	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—IGF1—hypothyroidism	0.000511	0.00421	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—IGF1—hypothyroidism	0.000511	0.00421	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000487	0.00401	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CLTC—hypothyroidism	0.000475	0.00391	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CLTC—hypothyroidism	0.000451	0.00371	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—PRL—hypothyroidism	0.000449	0.0037	CbGpPWpGaD
Thalidomide—PTGS1—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000439	0.00362	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CLTC—hypothyroidism	0.000427	0.00351	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—VAV3—hypothyroidism	0.000409	0.00336	CbGpPWpGaD
Thalidomide—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000405	0.00333	CbGpPWpGaD
Thalidomide—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000404	0.00333	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—VAV3—hypothyroidism	0.000388	0.00319	CbGpPWpGaD
Thalidomide—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000382	0.00314	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—IGF1—hypothyroidism	0.00036	0.00297	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	0.000348	0.00286	CbGpPWpGaD
Thalidomide—CYP2E1—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000328	0.0027	CbGpPWpGaD
Thalidomide—CYP3A5—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000328	0.0027	CbGpPWpGaD
Thalidomide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000312	0.00257	CbGpPWpGaD
Thalidomide—CYP1A1—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.00031	0.00255	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CLTC—hypothyroidism	0.000288	0.00237	CbGpPWpGaD
Thalidomide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000285	0.00234	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—IYD—hypothyroidism	0.000275	0.00227	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CLTC—hypothyroidism	0.000273	0.00225	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	0.000265	0.00218	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VAV3—hypothyroidism	0.000264	0.00217	CbGpPWpGaD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000253	0.00208	CbGpPWpGaD
Thalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000243	0.002	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ATP5O—hypothyroidism	0.000234	0.00193	CbGpPWpGaD
Thalidomide—PTGS1—Biological oxidations—POMC—hypothyroidism	0.000233	0.00192	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—VAV3—hypothyroidism	0.000233	0.00192	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000231	0.0019	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—VAV3—hypothyroidism	0.000221	0.00182	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TPO—hypothyroidism	0.00022	0.00181	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—IYD—hypothyroidism	0.000219	0.0018	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—IYD—hypothyroidism	0.000206	0.00169	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—IYD—hypothyroidism	0.000205	0.00169	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000204	0.00168	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VAV3—hypothyroidism	0.000201	0.00166	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000197	0.00162	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—IYD—hypothyroidism	0.000194	0.0016	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CLTC—hypothyroidism	0.000186	0.00153	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ATP5O—hypothyroidism	0.000186	0.00153	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CLTC—hypothyroidism	0.000177	0.00145	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ATP5O—hypothyroidism	0.000175	0.00144	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TPO—hypothyroidism	0.000175	0.00144	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ATP5O—hypothyroidism	0.000175	0.00144	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—POMC—hypothyroidism	0.000174	0.00144	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—POMC—hypothyroidism	0.000174	0.00143	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ATP5O—hypothyroidism	0.000165	0.00136	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TPO—hypothyroidism	0.000164	0.00135	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—POMC—hypothyroidism	0.000164	0.00135	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TPO—hypothyroidism	0.000164	0.00135	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	0.000164	0.00135	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000162	0.00133	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TRH—hypothyroidism	0.000161	0.00133	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—IYD—hypothyroidism	0.000159	0.00131	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TPO—hypothyroidism	0.000155	0.00128	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TRH—hypothyroidism	0.000153	0.00126	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PRL—hypothyroidism	0.000147	0.00121	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—IYD—hypothyroidism	0.000145	0.00119	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000144	0.00118	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TSHB—hypothyroidism	0.000144	0.00118	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TSHR—hypothyroidism	0.000144	0.00118	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PRL—hypothyroidism	0.000139	0.00115	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TSHB—hypothyroidism	0.000136	0.00112	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TSHR—hypothyroidism	0.000136	0.00112	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—VAV3—hypothyroidism	0.000136	0.00112	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ATP5O—hypothyroidism	0.000135	0.00111	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—POMC—hypothyroidism	0.000135	0.00111	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—VAV3—hypothyroidism	0.000129	0.00106	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PRL—hypothyroidism	0.000129	0.00106	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SH2B3—hypothyroidism	0.000128	0.00105	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPO—hypothyroidism	0.000127	0.00104	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—IYD—hypothyroidism	0.000124	0.00102	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ATP5O—hypothyroidism	0.000123	0.00101	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—POMC—hypothyroidism	0.000123	0.00101	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SH2B3—hypothyroidism	0.000121	0.000999	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000118	0.000968	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPO—hypothyroidism	0.000116	0.000952	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000107	0.000882	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ATP5O—hypothyroidism	0.000105	0.000865	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—POMC—hypothyroidism	0.000105	0.000863	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TSHB—hypothyroidism	0.000102	0.000839	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPO—hypothyroidism	9.89e-05	0.000814	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PRL—hypothyroidism	9.49e-05	0.000781	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	9.16e-05	0.000754	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3C2A—hypothyroidism	9.08e-05	0.000747	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PRL—hypothyroidism	9.01e-05	0.000741	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	8.96e-05	0.000737	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VAV3—hypothyroidism	8.78e-05	0.000723	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AVP—hypothyroidism	8.46e-05	0.000696	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VAV3—hypothyroidism	8.33e-05	0.000686	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TSHB—hypothyroidism	8.09e-05	0.000666	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AVP—hypothyroidism	8.03e-05	0.000661	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SLC5A5—hypothyroidism	7.63e-05	0.000628	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TSHB—hypothyroidism	7.61e-05	0.000627	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TSHB—hypothyroidism	7.6e-05	0.000625	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3C2A—hypothyroidism	7.21e-05	0.000593	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TSHB—hypothyroidism	7.18e-05	0.000591	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	7.11e-05	0.000585	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3C2A—hypothyroidism	6.79e-05	0.000559	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3C2A—hypothyroidism	6.77e-05	0.000557	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3C2A—hypothyroidism	6.4e-05	0.000527	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRL—hypothyroidism	6.39e-05	0.000526	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	6.31e-05	0.00052	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC5A5—hypothyroidism	6.06e-05	0.000498	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TSHB—hypothyroidism	5.87e-05	0.000483	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC5A5—hypothyroidism	5.7e-05	0.000469	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC5A5—hypothyroidism	5.69e-05	0.000468	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—hypothyroidism	5.62e-05	0.000463	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1—hypothyroidism	5.41e-05	0.000445	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC5A5—hypothyroidism	5.37e-05	0.000442	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TSHB—hypothyroidism	5.36e-05	0.000441	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—hypothyroidism	5.33e-05	0.000439	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3C2A—hypothyroidism	5.24e-05	0.000431	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	5.17e-05	0.000425	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1—hypothyroidism	5.13e-05	0.000422	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3C2A—hypothyroidism	4.77e-05	0.000393	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	4.71e-05	0.000388	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TSHB—hypothyroidism	4.58e-05	0.000377	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC5A5—hypothyroidism	4.4e-05	0.000362	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3C2A—hypothyroidism	4.08e-05	0.000336	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	4.03e-05	0.000331	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC5A5—hypothyroidism	4.01e-05	0.00033	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—hypothyroidism	3.99e-05	0.000328	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC5A5—hypothyroidism	3.43e-05	0.000282	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—hypothyroidism	3.17e-05	0.000261	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—hypothyroidism	2.98e-05	0.000245	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—hypothyroidism	2.98e-05	0.000245	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—hypothyroidism	2.81e-05	0.000231	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—hypothyroidism	2.3e-05	0.000189	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—hypothyroidism	2.1e-05	0.000173	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—hypothyroidism	1.79e-05	0.000148	CbGpPWpGaD
